Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.
The Atypical hemolytic uremic syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for the Atypical hemolytic uremic syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atypical hemolytic uremic syndrome and features dormant and discontinued projects.
Key Targets in the Atypical Hemolytic Uremic Syndrome Pipeline Drugs Market
The key targets in the Atypical Hemolytic Uremic Syndrome pipeline drugs market are Complement C5, Complement Factor D, Mannan Binding Lectin Serine Protease 2, C5a Anaphylatoxin Chemotactic Receptor 1, Complement Factor B, and Complement Factor H.
Atypical Hemolytic Uremic Syndrome Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Atypical Hemolytic Uremic Syndrome Drugs Market
The key MoA in the Nondiarrhea – Associated Hemolytic Uremic Syndrome pipeline drugs market are Complement C5 Inhibitor, Complement Factor D Inhibitor, Mannan Binding Lectin Serine Protease 2 Inhibitor, C5a Anaphylatoxin Chemotactic Receptor 1 inhibitor, Complement Factor B inhibitor, and Complement Factor H inhibitor.
Atypical Hemolytic Uremic Syndrome Drugs Market, By MoA
To get more insights on key MoA, download a free report sample
Key RoA in the Atypical Hemolytic Uremic Syndrome Pipeline Drugs Market
The key RoA in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline products market are oral, intravenous, and subcutaneous.
Atypical Hemolytic Uremic Syndrome Drugs Market, by RoA
To get more insights on key RoA, download a free report sample
Key Molecule Types in the Nondiarrhea - Associated Hemolytic Uremic Syndrome Pipeline Drugs Market
The different molecule types in the Nondiarrhea – Associated Hemolytic Uremic Syndrome Pipeline Drugs Market are Monoclonal Antibody, Small Molecule, Fusion Protein, Gene Therapy, Recombinant Protein, and Synthetic Peptide.
Nondiarrhea – Associated Hemolytic Uremic Syndrome Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free report sample
Major Companies in the Nondiarrhea - Associated Hemolytic Uremic Syndrome Pipeline Drugs Market
The major companies in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline drugs market are Alexion Pharmaceuticals Inc (Alexion), eleva GmbH, Omeros Corp, Aevitas Therapeutics Inc, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, ISU ABXIS Co Ltd, and Novartis AG.
Nondiarrhea – Associated Hemolytic Uremic Syndrome Pipeline Drugs Market, by Company
For more company insights, download a free report sample
Nondiarrhea - Associated Hemolytic Uremic Syndrome Pipeline Drugs Market Overview
Key Targets | Complement C5, Complement Factor D, Mannan Binding Lectin Serine Protease 2, C5a Anaphylatoxin Chemotactic Receptor 1, Complement Factor B, and Complement Factor H
|
Key Mechanisms of action | Complement C5 Inhibitor, Complement Factor D Inhibitor, Mannan Binding Lectin Serine Protease 2 Inhibitor, C5a Anaphylatoxin Chemotactic Receptor 1 inhibitor, Complement Factor B inhibitor, and Complement Factor H inhibitor |
Key Routes of Administration | Oral, Intravenous, And Subcutaneous |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Fusion Protein, Gene Therapy, Recombinant Protein, and Synthetic Peptide |
Major Companies | Alexion Pharmaceuticals Inc (Alexion), eleva GmbH, Omeros Corp, Aevitas Therapeutics Inc, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, ISU ABXIS Co Ltd, and Novartis AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome).
- The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome)
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alexion Pharmaceuticals Inc
ChemoCentryx Inc
Chugai Pharmaceutical Co Ltd
ImmunAbs Inc
ISU ABXIS Co Ltd
Novartis AG
Omeros Corp
Prestige BioPharma Ltd
Ra Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Tasly Biopharmaceuticals Co Ltd
Turgut Ilaclari AS
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Atypical Hemolytic Uremic Syndrome pipeline drugs market?
The key targets in the Atypical Hemolytic Uremic Syndrome pipeline drugs market are Complement C5, Complement Factor D, Mannan Binding Lectin Serine Protease 2, C5a Anaphylatoxin Chemotactic Receptor 1, Complement Factor B, and Complement Factor H.
-
What are the key mechanisms of action in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) pipeline drugs market?
The key mechanisms of action in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline drugs market are Complement C5 Inhibitor, Complement Factor D Inhibitor, Mannan Binding Lectin Serine Protease 2 Inhibitor, C5a Anaphylatoxin Chemotactic Receptor 1 inhibitor, Complement Factor B inhibitor, and Complement Factor H inhibitor.
-
What are the Key RoA in the Atypical Hemolytic Uremic Syndrome Pipeline Drugs Market?
The key RoA in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline products market are oral, intravenous, and subcutaneous.
-
What are the different molecule types in the Nondiarrhea - Associated Hemolytic Uremic Syndrome Pipeline Drugs Market?
The different molecule types in the Nondiarrhea – Associated Hemolytic Uremic Syndrome Pipeline Drugs Market are Monoclonal Antibody, Small Molecule, Fusion Protein, Gene Therapy, Recombinant Protein, and Synthetic Peptide.
-
What are the major companies in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) pipeline drugs market?
The major companies in the Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) pipeline drugs market are Alexion Pharmaceuticals Inc (Alexion), eleva GmbH, Omeros Corp, Aevitas Therapeutics Inc, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, ISU ABXIS Co Ltd, and Novartis AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.